These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 26822949)

  • 41. Retesting of women who are negative for a
    Lerner-Ellis J; Sopik V; Wong A; Lázaro C; Narod SA; Charames GS
    J Med Genet; 2020 Jun; 57(6):380-384. PubMed ID: 31784482
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients.
    Crawford B; Adams SB; Sittler T; van den Akker J; Chan S; Leitner O; Ryan L; Gil E; van 't Veer L
    Breast Cancer Res Treat; 2017 Jun; 163(2):383-390. PubMed ID: 28281021
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Germline genetic variants in men with prostate cancer and one or more additional cancers.
    Pilié PG; Johnson AM; Hanson KL; Dayno ME; Kapron AL; Stoffel EM; Cooney KA
    Cancer; 2017 Oct; 123(20):3925-3932. PubMed ID: 28657667
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Breast cancer-associated missense mutants of the PALB2 WD40 domain, which directly binds RAD51C, RAD51 and BRCA2, disrupt DNA repair.
    Park JY; Singh TR; Nassar N; Zhang F; Freund M; Hanenberg H; Meetei AR; Andreassen PR
    Oncogene; 2014 Oct; 33(40):4803-12. PubMed ID: 24141787
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Germline mutations in DNA repair genes may predict neoadjuvant therapy response in triple negative breast patients.
    Spugnesi L; Gabriele M; Scarpitta R; Tancredi M; Maresca L; Gambino G; Collavoli A; Aretini P; Bertolini I; Salvadori B; Landucci E; Fontana A; Rossetti E; Roncella M; Naccarato GA; Caligo MA
    Genes Chromosomes Cancer; 2016 Dec; 55(12):915-924. PubMed ID: 27328445
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Gene of the month: PALB2.
    Hamdan O; Nowak KM
    J Clin Pathol; 2023 Feb; 76(2):73-75. PubMed ID: 36600573
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Heterozygous PALB2 c.1592delT mutation channels DNA double-strand break repair into error-prone pathways in breast cancer patients.
    Obermeier K; Sachsenweger J; Friedl TW; Pospiech H; Winqvist R; Wiesmüller L
    Oncogene; 2016 Jul; 35(29):3796-806. PubMed ID: 26640152
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Germline mutations in the PALB2 gene are population specific and occur with low frequencies in familial breast cancer.
    Hellebrand H; Sutter C; Honisch E; Gross E; Wappenschmidt B; Schem C; Deissler H; Ditsch N; Gress V; Kiechle M; Bartram CR; Schmutzler RK; Niederacher D; Arnold N; Meindl A
    Hum Mutat; 2011 Jun; 32(6):E2176-88. PubMed ID: 21618343
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of the contribution of the three breast cancer susceptibility genes CHEK2, STK11, and PALB2 in non-BRCA1/2 French Canadian families with high risk of breast cancer.
    Guénard F; Pedneault CS; Ouellette G; Labrie Y; Simard J; ; Durocher F
    Genet Test Mol Biomarkers; 2010 Aug; 14(4):515-26. PubMed ID: 20722467
    [TBL] [Abstract][Full Text] [Related]  

  • 50. PALB2 analysis in BRCA2-like families.
    Adank MA; van Mil SE; Gille JJ; Waisfisz Q; Meijers-Heijboer H
    Breast Cancer Res Treat; 2011 Jun; 127(2):357-62. PubMed ID: 20582465
    [TBL] [Abstract][Full Text] [Related]  

  • 51. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene.
    Rahman N; Seal S; Thompson D; Kelly P; Renwick A; Elliott A; Reid S; Spanova K; Barfoot R; Chagtai T; Jayatilake H; McGuffog L; Hanks S; Evans DG; Eccles D; ; Easton DF; Stratton MR
    Nat Genet; 2007 Feb; 39(2):165-7. PubMed ID: 17200668
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Functional variant analyses (FVAs) predict pathogenicity in the BRCA1 DNA double-strand break repair pathway.
    Loke J; Pearlman A; Upadhyay K; Tesfa L; Shao Y; Ostrer H
    Hum Mol Genet; 2015 Jun; 24(11):3030-7. PubMed ID: 25652403
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Analysis of PALB2/FANCN-associated breast cancer families.
    Tischkowitz M; Xia B; Sabbaghian N; Reis-Filho JS; Hamel N; Li G; van Beers EH; Li L; Khalil T; Quenneville LA; Omeroglu A; Poll A; Lepage P; Wong N; Nederlof PM; Ashworth A; Tonin PN; Narod SA; Livingston DM; Foulkes WD
    Proc Natl Acad Sci U S A; 2007 Apr; 104(16):6788-93. PubMed ID: 17420451
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Exploring the link between MORF4L1 and risk of breast cancer.
    Martrat G; Maxwell CM; Tominaga E; Porta-de-la-Riva M; Bonifaci N; Gómez-Baldó L; Bogliolo M; Lázaro C; Blanco I; Brunet J; Aguilar H; Fernández-Rodríguez J; Seal S; Renwick A; Rahman N; Kühl J; Neveling K; Schindler D; Ramírez MJ; Castellà M; Hernández G; ; Easton DF; Peock S; Cook M; Oliver CT; Frost D; Platte R; Evans DG; Lalloo F; Eeles R; Izatt L; Chu C; Davidson R; Ong KR; Cook J; Douglas F; Hodgson S; Brewer C; Morrison PJ; Porteous M; Peterlongo P; Manoukian S; Peissel B; Zaffaroni D; Roversi G; Barile M; Viel A; Pasini B; Ottini L; Putignano AL; Savarese A; Bernard L; Radice P; Healey S; Spurdle A; Chen X; Beesley J; ; Rookus MA; Verhoef S; Tilanus-Linthorst MA; Vreeswijk MP; Asperen CJ; Bodmer D; Ausems MG; van Os TA; Blok MJ; Meijers-Heijboer HE; Hogervorst FB; ; Goldgar DE; Buys S; John EM; Miron A; Southey M; Daly MB; ; ; Harbst K; Borg A; Rantala J; Barbany-Bustinza G; Ehrencrona H; Stenmark-Askmalm M; Kaufman B; Laitman Y; Milgrom R; Friedman E; Domchek SM; Nathanson KL; Rebbeck TR; Johannsson OT; Couch FJ; Wang X; Fredericksen Z; Cuadras D; Moreno V; Pientka FK; Depping R; Caldés T; Osorio A; Benítez J; Bueren J; Heikkinen T; Nevanlinna H; Hamann U; Torres D; Caligo MA; Godwin AK; Imyanitov EN; Janavicius R; ; Sinilnikova OM; Stoppa-Lyonnet D; Mazoyer S; Verny-Pierre C; Castera L; de Pauw A; Bignon YJ; Uhrhammer N; Peyrat JP; Vennin P; Ferrer SF; Collonge-Rame MA; Mortemousque I; McGuffog L; Chenevix-Trench G; Pereira-Smith OM; Antoniou AC; Cerón J; Tominaga K; Surrallés J; Pujana MA
    Breast Cancer Res; 2011 Apr; 13(2):R40. PubMed ID: 21466675
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ethnicity-specific BRCA1, BRCA2, PALB2, and ATM pathogenic alleles in breast and ovarian cancer patients from the North Caucasus.
    Sokolenko AP; Bakaeva EK; Venina AR; Kuligina ES; Romanko AA; Aleksakhina SN; Belysheva YV; Belogubova EV; Stepanov IA; Zaitseva OA; Yatsuk OS; Togo AV; Khamgokov ZM; Kadyrova AO; Pirmagomedov AS; Bolieva MB; Epkhiev AA; Tsutsaev AK; Chakhieva MD; Khabrieva KM; Khabriev IM; Murachuev MA; Buttaeva BN; Baboshkina LS; Bayramkulova FI; Katchiev IR; Alieva LK; Raskin GA; Orlov SV; Khachmamuk ZK; Levonyan KR; Gichko DM; Kirtbaya DV; Degtyariov AM; Sultanova LV; Musayeva HS; Belyaev AM; Imyanitov EN
    Breast Cancer Res Treat; 2024 Jan; 203(2):307-315. PubMed ID: 37851290
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Analysis of PALB2 mutations in 155 Japanese patients with breast and/or ovarian cancer.
    Nakagomi H; Sakamoto I; Hirotsu Y; Amemiya K; Mochiduki H; Omata M
    Int J Clin Oncol; 2016 Apr; 21(2):270-275. PubMed ID: 26411315
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Germline mutations of multiple breast cancer-related genes are differentially associated with triple-negative breast cancers and prognostic factors.
    Hata C; Nakaoka H; Xiang Y; Wang D; Yang A; Liu D; Liu F; Zou Q; Wei L; Zheng K; Inoue I; You H
    J Hum Genet; 2020 Jul; 65(7):577-587. PubMed ID: 32029870
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mutation screening of PALB2 in clinically ascertained families from the Breast Cancer Family Registry.
    Nguyen-Dumont T; Hammet F; Mahmoodi M; Tsimiklis H; Teo ZL; Li R; Pope BJ; Terry MB; Buys SS; Daly M; Hopper JL; Winship I; Goldgar DE; Park DJ; Southey MC
    Breast Cancer Res Treat; 2015 Jan; 149(2):547-54. PubMed ID: 25575445
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Frequency of heterozygous germline pathogenic variants in genes for Fanconi anemia in patients with non-BRCA1/BRCA2 breast cancer: a meta-analysis.
    Alter BP; Best AF
    Breast Cancer Res Treat; 2020 Jul; 182(2):465-476. PubMed ID: 32488392
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Low prevalence of germline PALB2 mutations in Australian triple-negative breast cancer.
    Wong-Brown MW; Avery-Kiejda KA; Bowden NA; Scott RJ
    Int J Cancer; 2014 Jan; 134(2):301-5. PubMed ID: 23824750
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.